Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Nascent Biotech Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
NBIO
Over the counter
8731
https://www.nascentbiotech.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Nascent Biotech Inc
Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run
- Apr 16th, 2024 12:00 pm
Nascent Collaborates With Hypospray Pharma on Proprietary Transdermal Delivery System
- Mar 19th, 2024 12:00 pm
Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates
- Feb 6th, 2024 12:00 pm
Nascent Biotech Receives an Analyst Opinion Suggesting that of the Company is Significantly Under Valued
- Jan 9th, 2024 1:00 pm
Nascent Biotech Completes Payment of Variable Convertible Note in Full to Eliminate Dilution Risk
- Dec 19th, 2023 1:00 pm
Nascent Biotech Granted Japanese Patent for Crossing Blood-Brain Barrier
- Nov 29th, 2023 1:00 pm
Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer
- Aug 22nd, 2023 12:00 pm
Nascent Biotech Phase I Clinical Data Presented at the American Society of Clinical Oncology Annual Meeting
- Jun 7th, 2023 12:00 pm
Nascent Biotech Regains Worldwide Rights for Pritumumab
- May 26th, 2023 9:45 pm
Nascent Biotech to Present Phase I Clinical Data at American Society of Clinical Oncology Annual Meeting
- May 9th, 2023 12:00 pm
Scroll